



Review

ZIKA virus entry mechanisms in human cells

Almerinda Agrelli^{a,*}, Ronald Rodrigues de Moura^b, Sergio Crovella^{a,b},
Lucas André Cavalcanti Brandão^{a,c}

^a Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife CEP: 50670-901, Brazil

^b Department of Genetics, Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife CEP: 50670-901, Brazil

^c Department of Pathology, Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife CEP: 50670-901, Brazil

ARTICLE INFO

Keywords:

ZIKV
C-type lectin receptors
Apoptotic mimicry
ZIKV protein prM
ZIKV protein E

ABSTRACT

Zika virus (ZIKV) is an enveloped, mosquito-borne *Flavivirus*, which infects cells through clathrin-mediated endocytosis and fusion employing acidic endosomes. Cell entry is mostly mediated by the viral glycoprotein E, although incomplete particle maturation enables viral protein prM and anionic lipids present in the viral membrane to mediate this process. Incomplete proteolytic maturation results in a set of highly heterogeneous particles. These heterogeneous and dynamic infectious particles offer a variety of possible receptor interaction sites on their surfaces, thus contributing to the wide range of cells susceptible to ZIKV as well as to variation in tissue tropism. This review addresses recent advances in the understanding of ZIKV entry process into cells and put together fundamental questions about viral replication, maturation and host-cell interactions.

1. Introduction

Zika virus (ZIKV) is an arbovirus belonging to the *Flaviviridae* family, genus *Flavivirus*, closely related to several other viruses that cause disease globally, including Dengue (DENV), Yellow Fever (YFV), West Nile (WNV), Japanese Encephalitis (JEV) and Tick-borne Encephalitis Virus (TBEV) (Alam et al., 2017; Miner and Diamond, 2017; Musso et al., 2015; Wang et al., 2017a).

ZIKV was first isolated in 1947 from the serum of a sentinel Rhesus monkey at the Zika forest, in Uganda (Dick et al., 1952). The first evidence of human infection was based on the presence of neutralizing antibodies against ZIKV in 1952, and it was first linked to Zika disease in 1964 (Simpson, 1964). Nevertheless, little attention was paid to this virus until outbreaks were reported in Yap Island, Federated States of Micronesia, in 2007 (Duffy et al., 2009), and in French Polynesia, 2013 (Cao-Lormeau et al., 2014), where it was associated with Guillain-Barré Syndrome. During the outbreak in Brazil, in 2015, ZIKV was linked to neonatal microcephaly (ECDC, 2015; Schuler-faccini et al., 2016). To date, in Brazil, there were 16,735 suspected cases of changes in growth and development of children related to ZIKV infection, with 3267 (19,5%) confirmed cases (Brazil Ministry of Health, 2018). These severe clinical implications have prompted the scientific community to develop emergency interventions, since the disease pathogenic

mechanism is not yet completely understood.

ZIKV genome has ~10.7 kb, encoding 3423 amino acids, with two flanking 5' and 3' noncoding regions and a single long structure encoding a polyprotein, which is cleaved into capsid protein (C), precursor protein (prM), envelope protein (E) and 7 non-structural proteins (NS): 50-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-30 (Dikhit et al., 2016; Göertz et al., 2017). Viral envelope protein E intermediates membrane fusion by receptor-mediated endocytosis mostly through C-type lectin receptors family from the host-cell (Dai et al., 2016; Kim et al., 2017a). Although, cellular lipid receptors, such as TIM (T-cell immunoglobulin mucin) and TAM (Receptor tyrosine kinases: TYRO3, AXL and MER) receptor families (which recognize lipids in the viral membrane) showed to mediate ZIKV entry (Hastings et al., 2017; Liu et al., 2016; Meertens et al., 2017).

The molecules used by ZIKV in entry process depend on the pattern of proteins expressed in viral particle lattice and therefore appear to rely on the degree of particle maturation (Pierson and Diamond, 2013). Furthermore, cell type plays a major role in this mechanism (Perera-lecoin et al., 2014). Studies *in vivo* showed that cells of the reproductive tract (spermatogonia, sperm, Sertoli and Leydig cells) (Govero et al., 2016) and from cerebral cortex and hippocampus (Wang et al., 2017b) are permissive to ZIKV infection in mice. More importantly, using an *in vitro* approach, cell culture experiments demonstrated the ability of

* Corresponding author.

E-mail addresses: almerinda.agrelli@ufpe.br (A. Agrelli), ppgg@ufpe.br, ronald.moura@ufpe.br (R.R. de Moura), sergio.crovella@ufpe.br (S. Crovella), dpatologia@ufpe.br, lucas.cbrandao@ufpe.br (L.A.C. Brandão).

<https://doi.org/10.1016/j.meegid.2019.01.018>

Received 23 August 2018; Received in revised form 29 November 2018; Accepted 14 January 2019

Available online 15 January 2019

1567-1348/ © 2019 Elsevier B.V. All rights reserved.




Fig. 1. ZIKV processes of attachment and entry, replication, translation, assembly, maturation and release from infected cells.

ZIKV to infect human cells, such as skin fibroblasts (Hamel et al., 2015), uterine fibroblasts (Chen et al., 2016), primary placental trophoblasts and Hofbauer cells (Aagaard et al., 2017; Quicke et al., 2016), endometrial stromal cells (Pagani et al., 2017), and neural progenitor cells (Dang et al., 2016; Tang et al., 2016). These findings hold for an extensive set of cells susceptible to ZIKV infection and therefore a robust number of receptors involved in viral entry process. In this review, we discuss viral maturation and heterogeneity in the context of ZIKV entry, highlighting recent advances in the understanding of molecular mechanisms involved in viral infectivity.

2. CLATHRIN-mediated endocytosis

The main mechanism by which *Flavivirus* infiltrate human host cells is clathrin-mediated endocytosis, which is followed by a change in envelope conformation, membrane fusion and release of the viral genome (Fig. 1) (Cruz-Oliveira et al., 2015; Hackett and Cherry, 2018). Clathrin-mediated endocytosis is a vesicular trafficking process that transports cargo molecules from the cell surface to its interior, and generally occurs at specialized sites, where a “coated pit” structure is assembled in order to concentrate surface proteins for internalization (Mousavi et al., 2004). This process (named after the most abundant protein found in coated pits: clathrin) is mostly involved in physiological processes, such as nutrient uptake, cell signaling and adhesion, etc., however, the same mechanism has shown to be used by viruses, including ZIKV (Persaud et al., 2018), to enter cells (Kaksonen and Roux, 2018).

Initially, during viral infection, viral particles diffuse along the cell surface toward a pre-existing clathrin-coated pit. This implies that viruses either roll over distinct binding factors until they bind to the input receptor (located in clathrin hotspots on the cell surface), or that the initially formed virus-receptor complex is transported to a pre-existing clathrin-coated pit (Smit et al., 2011). Subsequently, the clathrin-coated pit evolves and invagination at the plasma membrane is closed by excision of the dynamin-mediated membrane to form a clathrin-coated vesicle. This vesicle is transported away from the plasma membrane, and then the clathrin coating is released from it. After clathrin-mediated uptake, the endocytic vesicle carrying the virus is delivered to the initial endosomes, which mature into late endosomes,

and then the viral membrane fuses with the endosome membrane so viral RNA is released into the cytoplasm (Mercer et al., 2010). It is important to note that membrane fusion on the host cell depends on the pH of the viral membrane and therefore may vary between different strains (Chu and Ng, 2004; Cruz-Oliveira et al., 2015).

3. Attachment factors and entry receptors

It is likely that receptor binding and recognition is a process where multiple molecules are used in combination for infectious entry (Kaufmann and Rossmann, 2012; Kim et al., 2017a; Mercer et al., 2010). The surface of ZIKV mature particle is typically covered by homodimers of protein E (E)₂, arranged in an icosahedral format (Sirohi et al., 2016). Individual interactions with human receptors are generally weak, but contact with multiple receptors makes avidity higher and the bind becomes stronger (Mercer and Helenius, 2010). It is important to distinguish entry receptors - interactions that result in virus uptake - from attachment factors, which will only retain viral particles on cell surface until there is interaction with an entry receptor (Kim et al., 2017a). Generally, receptors promote endocytosis and accompany the virus into the cell (Kaufmann and Rossmann, 2012). Therefore, entry starts with binding to attachment factors, followed by associations with one or more receptors.

The most commonly encountered attachment factors are negatively charged glycosaminoglycans (GAGs), such as heparan sulfate and chondroitin sulfate (Kim et al., 2017a), which can be utilized by several flaviviruses, including DENV (Hilgard and Stockert, 2000; Thepparit et al., 2004), WNV (Lee et al., 2004), JEV (Lee et al., 2004; Su et al., 2001) and TBEV (Kroschewski et al., 2003), as low-affinity attachment factors that concentrate the virus on the cell surface. Binding to these negatively charged polysaccharides is usually electrostatic and relatively nonspecific (Mercer et al., 2010). A surface plasmon resonance analysis that explored binding between GAGs prepared from placenta and protein E suggested that ZIKV may utilized GAGs as attachment factors for host cell entry, as other pathogenic flaviviruses (Kim et al., 2017b).

ZIKV entry into target cells is mostly mediated by interaction of N-glycans conjugated to protein E with cell surface receptors of the host cell (Hasan et al., 2017; Heinz and Stiasny, 2017). Protein E is the




Fig. 2. Structure of ZIKV E protein dimers (PDB id code: 5IZ7). (A) E protein domains I (red), II (yellow) and III (blue). Fusion loop (FL) is evidenced in the dotted circle. (B) Stem-transmembrane domain that anchors the protein into the membrane is shown in green. The glycosylation site (with the glycan, in pink) is found in the 150 loop region. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

largest viral surface protein, being involved in membrane binding and fusion processes (Hasan et al., 2017; Shi and Gao, 2017). In ZIKV, protein E is N-glycosylated after the translation process at position Asn154 (asparagine, at position 154) within a highly conserved N-X-T/S sequence glycosylation motif (in which N is asparagine, T is threonine and X is any standard amino acid, except proline) at positions 154–156, indicating the biological importance of this modification (Fontes-garfias et al., 2017). However, other *Flavivirus* do not exhibit such glycosylation, suggesting that protein E function can be achieved without N-glycan (Adams et al., 1995; Beasley et al., 2004).

Similar to other *Flavivirus*, ZIKV protein E has four domains: the stem-transmembrane domain, which is responsible for membrane anchoring; and domains I, II and III, which constitute the predominantly β -strand surface part of the protein (Heinz and Stiasny, 2017; Ye et al., 2016).

Domain I (DI) of protein E acts as a bridge between domains II (DII) and III (DIII) (Fig. 2a). The tip of DII contains the fusion loop (FL), which interacts with the host membrane during membrane fusion and is the most conserved structural element in this protein among all *Flavivirus* (Heinz and Stiasny, 2012). FL is responsible for the broad antibody cross-reactivity observed among all *Flavivirus* and plays an important role as an antigenic site that contributes to antibody-mediated enhancement of infection. A study based on chemical cross-linking and immunoassays demonstrated that monoclonal antibodies recognize epitopes at the interface of the dimeric envelope protein E, cause dimer dissociation and lead to the exposure of FL in TBEV and DENV (Haslwanter et al., 2017). Under usual infection conditions, this process

is only triggered after the virus contact with the acidic pH of endosomes, resulting in membrane fusion through the interaction of FL with the endosomal membrane (Mercer et al., 2010; Smit et al., 2011). This exposure of FL at neutral pH may mediate attachment of the virus to the plasma membrane, thereby increasing viral infectivity.

Receptor-binding site is localized on DIII, being of great importance in the fusion process. Curiously, ZIKV has a single glycosylation site (Asn154) on DI of protein E (Fig. 2b), which protrudes from the surface, because ZIKV E-DI has a longer “150 loop” (residues 145–160) compared to other flaviviruses. This 150 loop region varies not only between ZIKV strains but also in other *Flavivirus*, suggesting that variations in this region influence viral infectivity (Shi and Gao, 2017).

Virions are not static structures and undergo concerted fluctuations at equilibrium, a phenomenon referred to as viral “breathing” (Lewis et al., 1998). More recent evidence indicates that metastability of the E dimers gives rise to a dynamic motion, in which they transiently expose otherwise buried surfaces (Kuhn et al., 2015). These structural dynamics of the surface of the virus transiently expose the E-sites that would be inaccessible in a static viral particle with a closed envelope of 90 E dimers in a fishbone arrangement, as determined by cryo EM (Kostyuchenko et al., 2016). Dynamics of fully and partially mature particles may thus facilitate interactions with cellular attachment factors and entry receptors.

4. C-type lectin receptors

The innate immune system is responsible for the body's first line of

defense against microbial attack and it is induced by the recognition of microbial components, known as pathogen-associated molecular patterns (PAMPs). Such recognition initiates signaling cascades that induce the intracellular innate immune defenses and the inflammatory response which facilitates the development of the acquired immune response (Hoving et al., 2014; Kell and Gale Jr, 2015). Viruses are recognized by human pattern recognition receptors (PRRs) through their nucleic acids, such as double (dsRNA), single stranded-RNA (ssRNA), and DNA, although envelope glycoproteins on surface of viral particle can also be recognized as PAMPs (Hoving et al., 2014).

C-type lectin receptors (CLRs) comprise a large family of carbohydrate receptors, which bind through one or more carbohydrate recognition domains (CRDs), and is divided into 17 groups taking into account features such as phylogeny and structure (Zelensky and Gready, 2005). Several members of this family are highly expressed in myeloid cells, including monocytes, macrophages and dendritic cells, thus playing a central role in the activation of the host immune system (Kim et al., 2017a).

CLRs recognize carbohydrate profiles in pathogens and act as PRRs for the internalization of these agents, directing them to endosomes, initiating the process of antigen presentation and elimination of the pathogen (Cambi et al., 2005). The most implicated CLRs in *Flavivirus* entry are DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) (Hacker et al., 2009; Lozach et al., 2005; Navarro-Sanchez et al., 2003; Tassaneeritthep et al., 2003), L-SIGN (Liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin) (Navarro-Sanchez et al., 2003; Wang et al., 2016), MMR (Macrophage mannose receptor) (Miller et al., 2008) e CLEC5A (C-type lectin member 5A) (Chen et al., 2008).

DC-SIGN showed to permit ZIKV entry into cells (Hamel et al., 2015). Additionally, *in vitro* analysis carried out with different cell lineages revealed similar results with DENV (Alen et al., 2009; Hacker et al., 2009; Lozach et al., 2005; Tassaneeritthep et al., 2003), WNV (Davis et al., 2006b; Martina et al., 2008) and JEV (Shimojima et al., 2014), whereas L-SIGN demonstrated to enable cell entry only for WNV (Davis et al., 2006b) and JEV (Shimojima et al., 2014). Studies have identified a single nucleotide polymorphism in the promoter sequence of DC-SIGN gene (CD209) that is strongly associated with predisposition to dengue hemorrhagic fever (rs4804803) (Wang et al., 2011) and severe forms of tick-borne encephalitis (rs2287886) (Barkhash et al., 2012), which reinforces the involvement of this receptor in *Flavivirus* tropism.

DC-SIGN and its close homologue L-SIGN are group II (calcium-dependent with single CRD) transmembrane C-type lectins and interact through their CRD domains with carbohydrates bound to viral protein E (Cruz-Oliveira et al., 2015; Zelensky and Gready, 2005). Their extracellular domains share common structural motifs, including an extended neck composed of tandem repeats of a highly conserved 23-amino acid sequence, which is followed by a CRD that binds mannose-rich glycans and plays an important role in entry mechanisms of *Flavivirus* into myeloid cells (Khoo et al., 2008). DC-SIGN is highly expressed in some subsets of immature macrophages and dendritic cells, suggesting a possible facilitation in viral dissemination (Hamel et al., 2015; Kay et al., 2012; Smit et al., 2011). Contrarily, L-SIGN expression is restricted to sinusoidal endothelial cells of the liver and endothelial cells of lymph nodes (Tassaneeritthep et al., 2003), however its role during the course of infection has not yet been established (Perera-lecoinc et al., 2014).

MMR is a group VI (calcium-dependent with multiple CRDs) CLR that has been proposed to be a functional entry receptor for *Flavivirus* (Hafizi and Dahlbäck, 2006). Unlike DC-SIGN and L-SIGN, MMR has several CRD domains and a cysteine-rich domain at the end of its extracellular domain that is capable of interacting with sulfated sugars (Hamel et al., 2015; Martinez-pomares, 2012). MMR is essentially expressed in macrophages, but can also be found in lymph nodes and endothelial cells of the liver, in kidney cells and in some dendritic cells

populations (Martinez-pomares, 2012) - all relevant to *Flavivirus* infection. This receptor demonstrated to bind protein E of four DENV serotypes and was proposed as a DENV internalization receptor in human primary macrophages, since anti-MMR polyclonal antibodies inhibit virus infection (Dejnirattisai et al., 2016). CLEC5A is a group V CLR (calcium-independent with single CRD) (Kim et al., 2017a), which is expressed in monocytes and macrophages and has showed to mediate the entry of DENV (Chen et al., 2008) and JEV (Chen et al., 2012) into cells. Even though strong evidence link L-SIGN, MMR and CLEC5A to *Flavivirus* entry, we did not find in literature studies relating these receptors particularly in ZIKV entry process. Nevertheless, considering the similarity between these viruses, it is possible that ZIKV explores multiple CLRs for entry and greater viral spread.

5. Entry mediated by negatively charged lipids

Previous studies indicate that the entry process of flaviviruses, including ZIKV, may be mediated by interactions that do not involve protein E, but occur between negatively charged lipids, such as phosphatidylserine (PS), present in the viral membrane (Cruz-Oliveira et al., 2015; Hafizi and Dahlbäck, 2006; Hamel et al., 2015; Heinz and Stiasny, 2017; Meertens et al., 2012; Perera-lecoinc et al., 2014). These anionic lipid cell receptors belong to two distinct families of transmembrane phosphatidylserine receptors: TIM (TIM1, TIM3 and TIM4) and TAM (TYRO3, AXL and MER) (Kay et al., 2012; Lemke and Rothlin, 2010; Meertens et al., 2012).

On the contrary of TIM receptors, TAM receptors do not bind directly to PS, but indirectly, through a process that requires the presence of GAS6 (Growth-arrest-specific 6) or PROS (Protein S), which act as bridging molecules (Hafizi and Dahlbäck, 2006; Lemke and Rothlin, 2010; Meertens et al., 2012). The physiological function of these receptors is to recognize negatively charged lipids in apoptotic cells and trigger endocytosis by phagocytic cells (Fairn et al., 2011; Mercer and Helenius, 2010). This process of “kidnapping” was previously identified in a large number of viruses and is called “apoptotic mimicry” (Amara and Mercer, 2015).

As *Flavivirus* sprouts in the lumen of the endoplasmic reticulum (ER) during morphogenesis, the viral membrane ends up reflecting the ER membrane composition, which has PS in its luminal leaflet. The plasma membrane of living cells normally does not contain negatively charged lipids in the external leaflet due to the presence of specific enzymes called “lipid flippers” that assure the asymmetry of the plasmatic membrane by keeping these lipids only in the internal leaflet (Fairn et al., 2011; Kay et al., 2012).

The role of phosphatidylserine receptors in the entry of *Flavivirus* into cells was first identified in DENV studies, but several evidences suggest that ZIKV can also use apoptotic mimicry to infect different human tissues, including skin cells (Hamel et al., 2015), endothelial cells (Liu et al., 2016), neural cells (Retallack et al., 2016; Tang et al., 2016; Wells et al., 2016), and placenta cells (Tabata et al., 2016). A study carried out with a TAM-knockout mice demonstrated that these molecules are not necessary for ZIKV infectivity and virus replication has not been affected in the spleen, placenta, vagina and brain (Hastings et al., 2017). The data corroborate with previous observations (Govero et al., 2016) and suggest that there may be redundancy of ZIKV input receptors in cells.

Interestingly, a recent case series where placental tissues (from women who had laboratory-confirmed ZIKV during pregnancy) were analyzed showed that Hofbauer cells sustain the presence of the virus in the placenta until birth and may provide a viral source for continued infection (Noronha et al., 2018). Additionally, a sophisticated model of uterine-placental route of transmission was suggested by Tabata et al., 2016. This model proposes that ZIKV may disseminate by infecting invasive cytotrophoblasts (CTBs), which leave from chorionic villus of the placenta and surpass uterine wall to remodel uterine arteries. Once in contact with maternal infected blood, CTBs get infected and may

infect trophoblast progenitor cells in the chorionic membrane and then amniotic epithelial cells in the amniotic membrane. Thus, virions released into amniotic fluid may infect cells from the fetus. This elegant work also reported that TIM1 plays a critical role in the uterine-placental interface once its inhibitor blocked ZIKV infection *in vitro*. These data reinforce the involvement of phosphatidylserine receptors in ZIKV entry mechanism and raise questions on the possibility of an underlying cell-to-cell transmission mechanism. Further investigations on virion-synapses are required to elucidate ZIKV infectivity processes.

6. Role of particle maturation in ZIKV infectivity and prM as a putative entry receptor

Maturation of *Flavivirus* from immature particles (C, prM and E) to mature form (C, M and E) occurs during viral exocytosis of an infected cell (Dowd et al., 2014). During entry into the host cell, the acidic endosomal environment triggers an irreversible conformational change in protein E and a transition from a homodimer (E)₂ to a homotrimer (E)₃ formation - the final, lowest-energy conformation of E, which leads to membrane fusion and release of viral genetic material and further replication and translation processes (Yu et al., 2014). In ER, during particle assembly process, the immature newly assembled particle exhibits a spiny surface, with 180 prM-E heterodimers associated into 60 trimeric projections (prM-E)₃ (Fig. 3a). During viral maturation, the low pH within the trans-Golgi network induces a reorganization of (prM-E)₃ trimeric projections into 90 dimers (prM-E)₂ (Yu et al., 2014). This structural rearrangement exposes the cleavage site of prM to be digested by the host protease, furin (Heinz and Stiasny, 2012). The “pr” portion cleaved from prM remains associated with the virus until the cell is released, where it finally dissociates, due to the neutral pH of the extracellular medium (Zhang et al., 2007).

Fully mature particles incorporate proteins E (E)₂ and M (M)₂ as 90 homodimers each (Fig. 3b), arranged in closely packed protein shell with a herringbone pattern, and lacking non-cleaved prM protein (Yu et al., 2014). Several lines of evidence indicate that cleavage of prM may be inefficient and that infectious viral particles released from the cells may have non-cleaved prM. The resulting particles, therefore, exhibit a heterogeneous architecture, exposing both mature and immature particle structure (Fig. 3c) (Rey et al., 2017; Yu et al., 2014).

Heterogeneity of viral particles appears to be necessary for the use of apoptotic mimicry in the entry process of ZIKV into cells because the viral membrane containing PS would not be accessible in the mature viruses (Smit et al., 2011). We did not find any reports in literature about *in vitro* assays that exploited the maturation status of ZIKV particles to their phosphatidylserine receptor-mediated entry ability. It must be noted that different *Flavivirus*, or even different strains of the same virus, are likely to demonstrate different degrees of membrane exposure and may therefore differ in the use of entry lipid receptors.

The release of partially mature but infectious particles suggests that

prM or prM-E complex exposed on the surface of these particles could mediate viral entry process (Heinz and Stiasny, 2017). DENV has previously shown to be particularly rich in partially mature particles, since a sub-optimal furin cleavage motif in prM has evolved, exhibiting a conserved amino acid residue at the P3 cleavage position, which has shown to have a negative effect on the efficiency of furin cleavage (Junjhon et al., 2008). Thus, partial maturation seems to be important in the maintenance of viral ecological cycle. Another study conducted with WNV has demonstrated that N-glycosylated prM can mediate viral entry into cells via DC-SIGN (Davis et al., 2006a). A single mutation in prM (serine to asparagine substitution at position 139) has been associated with the ability of ZIKV to infect cells (Yuan et al., 2017), suggesting that prM could also act as an entry receptor.

6.1. Inhibition of ZIKV entry

Since ZIKV infection has become a serious public health issue, many efforts have been made to develop an anti-ZIKV drug. In this regard, many molecules demonstrated to be promising inhibitors of different stages of ZIKV's life cycle, such as viral entry, replication, maturation and release of infectious particles, although until date there is still no specific drug or vaccine against ZIKV infection (Munjal et al., 2017).

Concerning ZIKV entry, some molecules are known to block early viral mechanisms: by interfering with receptor binding or inhibiting internalization by endocytosis. Studies *in vitro* performed on different cell lines showed that curcumin (Mounce et al., 2017), nanchangmycin (Rausch et al., 2017), ZINC33683341 and ZINC49605556 (Sandun et al., 2016) molecules inhibit viral entry by blocking receptor binding, while compounds such as chloroquine (Li et al., 2017b; Shiryayev et al., 2017), suramin (Albulescu et al., 2017; Tan et al., 2017) and 25-hydroxycholesterol (Li et al., 2017a) demonstrated to inhibit ZIKV internalization *in vitro* and *in vivo*. Chloroquine's is controversial about its mechanism of action, whether if it is in viral entry or autophagic flux. Several tests *in vitro* and *in vivo* were carried out on both perspectives and appear to evidence a double mechanism for this drug (Cao et al., 2017; Li et al., 2017b; Liang et al., 2016; Shiryayev et al., 2017; Zhang et al., 2017). Apart from blocking receptor binding by targeting AXL, nanchangmycin also seems to play a double role by inhibiting clathrin-mediated endocytosis (Rausch et al., 2017). Further, arbutol, a well-known antiviral of broad-spectrum, showed to prevent an early step of ZIKV's lifecycle *in vitro*, although its precise mechanism of action is not well known yet (Fink et al., 2018). Epigallocatechin gallate (EGCG), a compound largely present in green tea, demonstrated to considerably reduce ZIKV infectivity in Vero cells, however its action seems to be viricidal by directly interacting with ZIKV's envelope (Carneiro et al., 2016). Additional tests with these drugs are clearly necessary for the development of a safe and effective treatment against ZIKV. We summarized the mechanisms of these anti-ZIKV drugs in Table 1.




Fig. 3. Viral particle possible structures. (A) Immature particle displaying trimeric projections (prM-E)₃ due to neutral pH of endoplasmic reticulum. (B) Mature particle displaying E (E)₂ and M (M)₂ homodimers after complete cleavage by furin and secretion from host cells. (C) Heterogeneous particle structure.

Table 1
List of potential inhibitors of early stage in ZIKV infection.

| Compound | Study model | Effects | Putative mechanism of action | Reference |
|-------------------------------|------------------------------------|---|---|--|
| Arbidol | <i>In vitro</i> | Inhibits viral infection of primary vaginal (HVE2) and cervical epithelial cells (ENDO and ECTO cells) and reduces the production of progeny virions | Inhibits an early step in viral lifecycle | (Fink et al., 2018) |
| Chloroquine | <i>In vitro</i> / <i>In vivo</i> | Inhibits viral infection <i>in vitro</i> (BHK-21, Huh7 and Vero cells) and attenuates ZIKV-associated morbidity and mortality in mice | Blocks viral internalization | (Li et al., 2017b) |
| Curcumin EGCG | <i>In vitro</i> | Reduces infectivity in HeLa, BHK-21 and Vero cells Reduces infectivity in Vero cells | Inhibits viral entry by interfering with the binding of protein E Virucidal effect probably by direct interaction of the drug with lipid envelope, leading to a subsequent destruction of the virus particle | (Mounce et al., 2017) (Carneiro et al., 2016) |
| Nanchangmycin | <i>In vitro</i> | Blocks ZIKV replication in U2OS cells | Targets AXL receptors and blocks clathrin-mediated endocytosis | (Rausch et al., 2017) |
| Suramin | <i>In vitro</i> | Inhibits viral attachment and the release of infectious progeny in Vero cells | Inhibits viral replication by preventing viral adsorption, entry and replication. | (Albulescu et al., 2017; Tan et al., 2017) |
| ZINC33683341 and ZINC49605556 | <i>In silico</i> / <i>In vitro</i> | Inhibits viral replication in Vero cells | Inhibits the function of protein E by binding the viral receptors | (Sandun et al., 2016) |
| 25-hydroxycholesterol | <i>In vitro</i> / <i>In vivo</i> | Inhibits viral infection <i>in vitro</i> (A549, BHK-21, HeLa and Vero cells), reduces the morbidity and mortality in mice and considerably reduces fever and viremia in monkeys | Inhibits viral entry possibly blocking viral internalization | (Li et al., 2017a) |

7. Conclusions

Current studies suggest that ZIKV produces an ensemble of structurally different virions circulating in an organism, collectively contributing to virus dissemination and tissue tropism. Considering that apoptotic mimicry may be used by ZIKV as an entry mechanism and that prM has also showed to be able to mediate this process, the release of immature particles may be advantageous for the virus, as it would increase the range of ZIKV susceptible cells. Thus, the degree of viral particle maturation and the amount of prM, E and PS exposed on the surface of the virus seem to be determinant in ZIKV entry mechanism in cells and appear to safeguard viral evolutionary processes of infectivity. Further studies regarding the role of viral particle maturation, the tropism and the cellular receptors involved in ZIKV entry are needed.

Acknowledgements

This study was financed by the National Council for the Improvement of Higher Education – Brazil (CAPES) – Finance Code 001, National Council for Scientific and Technological Development - Brazil (CNPq) and the Department of Science and Technology of the Ministry of Health - Brazil (Decit/SCTIE/MS).

Declarations of interest

None.

References

- Aagaard, K.M., Lahon, A., Suter, M.A., Arya, R.P., Seferovic, M.D., Vogt, M.B., Hu, M., Stossi, F., Mancini, M.A., Harris, R.A., Kahr, M., Eppes, C., Rac, M., Belfort, M.A., Park, C.S., Lacorazza, D., Rico-hesse, R., 2017. Primary human placental trophoblasts are permissive for Zika Virus (ZIKV) Replication. *Nat. Publ. Group* 7, 1–14. <https://doi.org/10.1038/srep41389>.
- Adams, S.C., Broom, A.K., Sammels, L.M., Hartnett, A.C., Howard, M.J., Coelen, R.J., Mackenzie, J.S., Hall, R.A., 1995. Glycosylation and antigenic variation among kunjin virus isolates. *Virology* 206, 49–56. [https://doi.org/10.1016/S0042-6822\(95\)80018-2](https://doi.org/10.1016/S0042-6822(95)80018-2).
- Alam, A., Imam, N., Farooqui, A., Ali, S., Malik, M.Z., Ishrat, R., 2017. Recent trends in ZIKV research: a step away from cure. *Biomed. Pharmacother.* 91, 1152–1159. <https://doi.org/10.1016/j.biopha.2017.05.045>.
- Albulescu, I.C., Kovacicova, K., Tas, A., Snijder, E.J., Van Hemert, M.J., 2017. Suramin inhibits ZIKA virus replication by interfering with virus attachment and release of infectious particles. *Antivir. Res.* 143, 230–236. <https://doi.org/10.1016/j.antiviral.2017.04.016>.
- Alen, M.M.F., Kaptein, S.J.F., De Burghgraef, T., Balzarini, J., Neyts, J., Schols, D., 2009. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. *Virology* 387, 67–75. <https://doi.org/10.1016/j.virol.2009.01.043>.
- Amara, A., Mercer, J., 2015. Viral apoptotic mimicry. *Nat. Rev. Microbiol.* 13, 461–469. <https://doi.org/10.1038/nrmicro3469>.
- Barkhash, A.V., Perelygin, A.A., Babenko, V.N., Brinton, M.A., Voevoda, M.I., 2012. Single nucleotide polymorphism in the promoter region of the CD209 gene is associated with human predisposition to severe forms of tick-borne encephalitis. *Antivir. Res.* 93, 64–68. <https://doi.org/10.1016/j.antiviral.2011.10.017>.
- Beasley, D.W.C., Davis, C.T., Estrada-Franco, J., Navarro-Lopez, R., Campomanes-Cortes, A., Tesh, R.B., Weaver, S.C., Barrett, A.D.T., 2004. Genome sequence and attenuating mutations in west Nile virus isolate from Mexico. *Emerg. Infect. Dis.* 10, 2221–2224. <https://doi.org/10.3201/eid1012.040647>.
- Brazil Ministry of Health, 2018. Monitoramento integrado de alterações no crescimento e desenvolvimento relacionadas à infecção pelo vírus ZIKA e outras etiologias infecciosas, até a semana epidemiológica 40 de 2018.
- Cambi, A., Koopman, M., Figdor, C.G., 2005. How C-type lectins detect pathogens. *Cell. Microbiol.* 7, 481–488. <https://doi.org/10.1111/j.1462-5822.2005.00506.x>.
- Cao, B., Parnell, L.A., Diamond, M.S., Mysorekar, I.U., 2017. Inhibition of autophagy limits vertical transmission of ZIKA virus in pregnant mice. *J. Exp. Med.* 214, 2303.
- Cao-Lormeau, V.-M., Roche, C., Teissier, A., Robin, E., Berry, A.-L., Mallet, H.-P., Sall, A.A., Musso, D., 2014. ZIKA virus, french polynesia, south pacific, 2013. *Emerg. Infect. Dis.* 20, 1960. <https://doi.org/10.3201/eid2011.141380>.
- Carneiro, B.M., Batista, M.N., Cláudia, A., Braga, S., Nogueira, M.L., Rahal, P., 2016. The green tea molecule EGCG inhibits ZIKA virus entry. *Virology* 496, 215–218. <https://doi.org/10.1016/j.virol.2016.06.012>.
- Chen, S.T., Lin, Y.L., Huang, M.T., Wu, M.F., Cheng, S.C., Lei, H.Y., Lee, C.K., Chiou, T.W., Wong, C.H., Hsieh, S.L., 2008. CLEC5A is critical for dengue-virus-induced lethal disease. *Nature* 453, 672–676. <https://doi.org/10.1038/nature07013>.
- Chen, S., Liu, R., Wu, M., Lin, Y., Chen, S., Tan, D.T., 2012. CLEC5A Regulates Japanese encephalitis virus-induced neuroinflammation and lethality. *PLoS Pathog.* 8. <https://doi.org/10.1371/journal.ppat.1002655>.

- Chen, J.C., Wang, Z., Huang, H., Weitz, S.H., Wang, A., Qiu, X., Baumeister, M.A., Uzgiris, A., Matias, M., Wang, Z., Rodriguez, J., Cruz, S., 2016. Infection of human uterine fibroblasts by ZIKA virus in vitro: implications for viral transmission in women. *Int. J. Infect. Dis.* 51, 139–140. <https://doi.org/10.1016/j.ijid.2016.07.015>.
- Chu, J.J.H., Ng, M.L., 2004. Infectious entry of west nile virus occurs through a clathrin-mediated endocytic pathway infectious entry of west nile virus occurs through a clathrin-mediated endocytic pathway. *J. Virol.* 78, 10543–10555. <https://doi.org/10.1128/JVI.78.19.10543>.
- Cruz-Oliveira, C., Freire, J.M., Conceição, T.M., Higa, L.M., Castanho, M.A.R.B., Da Poian, A.T., 2015. Receptors and routes of dengue virus entry into the host cells. *FEMS Microbiol. Rev.* 39, 155–170. <https://doi.org/10.1093/femsre/fuu004>.
- Dai, L., Song, J., Lu, X., Deng, Y.Q., Musyoki, A.M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., Xiao, H., Yan, J., Shi, Y., Qin, C.F., Qi, J., Gao, G.F., 2016. Structures of the ZIKA virus envelope protein and its complex with a flavivirus broadly protective antibody. *Cell Host Microbe* 19, 696–704. <https://doi.org/10.1016/j.chom.2016.04.013>.
- Dang, J., Tiwari, S.K., Lichinchi, G., Qin, Y., Patil, V.S., Eroshkin, A.M., Rana, T.M., 2016. ZIKA virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. *Stem Cells* 19, 258–265. <https://doi.org/10.1016/j.stem.2016.04.014>.
- Davis, C.W., Mattei, L.M., Nguyen, H., Ansarah-sobrinho, C., Doms, R.W., Pierson, T.C., 2006a. The location of asparagine-linked glycans on west nile virions controls their interactions with CD209 (Dendritic Cell-specific ICAM-3 Grabbing Nonintegrin) *. *J. Biol. Chem.* 281, 37183–37194. <https://doi.org/10.1074/jbc.M605429200>.
- Davis, C.W., Nguyen, H., Hanna, S.L., Sa, M.D., Doms, R.W., Pierson, T.C., 2006b. West nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. *J. Virol.* 80, 1290–1301. <https://doi.org/10.1128/JVI.80.3.1290>.
- Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., Sakuntabhai, A., Cao-Lormeau, V.M., Malasit, P., Rey, F.A., Mongkolsapaya, J., Screaton, G.R., 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with ZIKA virus. *Nat. Immunol.* 17, 1102–1108. <https://doi.org/10.1038/ni.3515>.
- Dick, G.W.A., Kitchen, S.F., Haddow, A.J., 1952. ZIKA virus. I. Isolations and serological specificity. *Trans. R. Soc. Trop. Med. Hyg.* 46, 509–520.
- Dikhit, M.R., Ansari, Y., Trivedi, K., Mansuri, R., Sahoo, B.R., Dehury, B., Amit, A., Roshan, K., Sahoo, G.C., Ali, V., Bimal, S., Das, P., 2016. Computational prediction and analysis of potential antigenic CTL epitopes in ZIKA virus: a first step towards vaccine development. *Infect. Genet. Evol.* 45, 187–197. <https://doi.org/10.1016/j.meegid.2016.08.037>.
- Dowd, K.A., Mukherjee, S., Kuhn, R.J., Pierson, C., 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. *J. Virol.* 88, 11726–11737. <https://doi.org/10.1128/JVI.01140-14>.
- Duffy, M.R., Chen, T.H., Hancock, W.T., Powers, A.M., Kool, J.L., Lanciotti, R.S., Pretrick, M., Marfel, M., Holzbauer, S., Dubray, C., Guillaumot, L., Griggs, A., Bel, M., Lambert, A.J., Laven, J., Kosoy, O., Panella, A., Biggerstaff, B.J., Fischer, M., Hayes, E.B., 2009. ZIKA virus outbreak on yap island, federated states of micronesia. *N. Engl. J. Med.* 360, 2536–2543. <https://doi.org/10.1056/NEJMoa0805715>.
- ECDC, E.C. for D.P. and C., 2015. Rapid Risk Assessment: ZIKA Virus Epidemic in the Americas: Potential Association with Microcephaly and Guillain-Barré Syndrome, 10 December 2015. European Centre for Disease Prevention and Control, Stockholm.
- Fairn, G.D., Schieber, N.L., Ariotti, N., Murphy, S., Kuerschner, L., Webb, R.I., Grinstein, S., Parton, R.G., 2011. High-resolution mapping reveals topologically distinct cellular pools of phosphatidyserine. *J. Cell Biol.* 194, 257–275. <https://doi.org/10.1083/jcb.201012028>.
- Fink, S.L., Vojtech, L., Wagoner, J., Slivinski, N.S.J., Jackson, K.J., Wang, R., Khadka, S., Luthra, P., Basler, C.F., Polyak, S.J., 2018. The antiviral drug arbidol inhibits ZIKA virus. *Sci. Rep.* 8, 8989. <https://doi.org/10.1038/s41598-018-27224-4>.
- Fontes-garfias, C.R., Shan, C., Luo, H., Muruato, A.E., Medeiros, B.A., Mays, E., Xie, X., Zou, J., Roundy, C.M., Rossi, S.L., Wang, T., Weaver, S.C., 2017. Functional analysis of glycosylation of ZIKA virus envelope protein. *Cell Rep.* 21, 1180–1190. <https://doi.org/10.1016/j.celrep.2017.10.016>.
- Goërtz, G.P., Abbo, S.R., Fros, J.J., Pijlman, G.P., 2017. Functional RNA during ZIKA virus infection. *Virus Res.* 1–13. <https://doi.org/10.1016/j.virusres.2017.08.015>.
- Govero, J., Esakky, P., Scheaffer, S.M., Fernandez, E., Drury, A., Platt, D.J., Gorman, M.J., Richner, J.M., Caine, E.A., Salazar, V., Moley, K.H., Diamond, M.S., 2016. ZIKA virus infection damages the testes in mice. *Nature* 540, 438–442.
- Hacker, K., White, L., de Silva, A.M., 2009. N-linked glycans on dengue viruses grown in mammalian and insect cells. *J. Gen. Virol.* 90, 2097–2106. <https://doi.org/10.1099/vir.0.012120-0>.
- Hackett, B.A., Cherry, S., 2018. Flavivirus internalization is regulated by a size-dependent endocytic pathway. *Proc. Natl. Acad. Sci. U. S. A.* 1–6. <https://doi.org/10.1073/pnas.1720032115>.
- Hafizi, S., Dahlbäck, B., 2006. Gas6 and protein S Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. *FEBS J.* 273, 5231–5244. <https://doi.org/10.1111/j.1742-4658.2006.05529.x>.
- Hamel, R., Dejarnac, O., Wicht, S., Ekchariyawat, P., Neyret, A., Luplertlop, N., Pereraleco, M., Surasombattana, P., Taligiani, L., Thomas, F., Cao-lormeau, V., Choumet, V., Briant, L., Desprès, P., Amara, A., Yssel, H., 2015. Biology of ZIKA virus infection in human skin cells. *J. Virol.* 89, 8880–8896. <https://doi.org/10.1128/JVI.00354-15>.
- Hasan, S.S., Miller, A., Sapparapu, G., Fernandez, E., Klose, T., Long, F., Fokine, A., Porta, J.C., Jiang, W., Diamond Jr., M.S., C. J.E., Kuhn, R.J., Rossmann, M.G., 2017. A human antibody against ZIKA virus crosslinks the E protein to prevent infection. *Nat. Commun.* 8, 1–6. <https://doi.org/10.1038/ncomms14722>.
- Haslwanter, D., Blaas, D., Heinz, F.X., Stiasny, K., 2017. A novel mechanism of antibody-mediated enhancement of flavivirus infection. *PLoS Pathog.* 13, 1–27. <https://doi.org/10.1371/journal.ppat.1006643>.
- Hastings, A.K., Yockey, L.J., Jagger, B.W., Fikrig, E., Diamond, M.S., Iwasaki, A., Hastings, A.K., Yockey, L.J., Jagger, B.W., Hwang, J., Uraki, R., Gaitsch, H.F., 2017. TAM receptors are not required for ZIKA virus infection in mice article TAM receptors are not required for ZIKA virus infection in mice. *Cell Rep.* 19, 558–568. <https://doi.org/10.1016/j.celrep.2017.03.058>.
- Heinz, F.X., Stiasny, K., 2012. Flaviviruses and their antigenic structure. *J. Clin. Virol.* 55, 289–295. <https://doi.org/10.1016/j.jcv.2012.08.024>.
- Heinz, F.X., Stiasny, K., 2017. The antigenic structure of zika virus and its relation to other flaviviruses: implications for infection and immunoprophylaxis. *Microbiol. Mol. Biol. Rev.* 81, 16. <https://doi.org/10.1128/MMBR.00055-16>. (e00055).
- Hilgard, P., Stockert, R., 2000. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. *Hepatology* 32, 1069–1077. <https://doi.org/10.1053/jhep.2000.18713>.
- Hoving, J.C., Wilson, G.J., Brown, G.D., Town, C., Africa, S., 2014. Microreview signalling C-type lectin receptors, microbial recognition and immunity. 16, 185–194. <https://doi.org/10.1111/cmi.12249>.
- Junjhon, J., Lausumpao, M., Supasa, S., Noisakran, S., Songjaeng, A., Saraithong, P., Chaichoun, K., Utaipat, U., Keelapang, P., Kanjanahaluethai, A., Puttikhunt, C., Kasinrer, W., Malasit, P., Sittisombut, N., 2008. Differential modulation of prM Cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfuran consensus positions of the dengue virus pr-M junction. *J. Virol.* 82, 10776–10791. <https://doi.org/10.1128/JVI.01180-08>.
- Kaksonen, M., Roux, A., 2018. Mechanisms of clathrin-mediated endocytosis. *Nat. Publ. Group* 19. <https://doi.org/10.1038/nrm.2017.132>.
- Kaufmann, B., Rossmann, M.G., 2012. Molecular mechanisms involved in the early steps of flavivirus cell entry. *Microbes Infect.* 13, 1–9. <https://doi.org/10.1016/j.micinf.2010.09.005>.
- Kay, J.G., Koivusalo, M., Ma, X., Wohland, T., Grinstein, S., Gruenberg, J.E., 2012. Phosphatidyserine dynamics in cellular membranes. *Mol. Biol. Cell* 23, 2198–2212. <https://doi.org/10.1091/mbc.E11-11-0936>.
- Kell, A.M., Gale Jr., M., 2015. RIG-I in RNA virus recognition. *Virology* 110–121. <https://doi.org/10.1016/j.coviro.2015.09.001>.
- Khoo, U.S., Chan, K.Y.K., Chan, V.S.F., Lin, C.L.S., 2008. DC-SIGN and L-SIGN: the SIGNS for infection. *J. Mol. Med.* 86, 861–874. <https://doi.org/10.1007/s00109-008-0350-2>.
- Kim, S.Y., Li, B., Linhardt, R.J., 2017a. Pathogenesis and inhibition of flaviviruses from a carbohydrate perspective. *Pharmaceuticals* 10, 1–24. <https://doi.org/10.3390/ph10020044>.
- Kim, S.Y., Zhao, J., Liu, X., Fraser, K., Lin, L., Zhang, X., Zhang, F., Dordick, J.S., Linhardt, R.J., 2017b. Interaction of ZIKA virus envelope protein with glycosaminoglycans. *Biochemistry* 56, 1151–1162. <https://doi.org/10.1021/acs.biochem.6b01056>.
- Kostyuchenko, V.A., Lim, E.X., Zhang, S., Fibransah, G., Ng, T., Ooi, J.S.G., Shi, J., Lok, S., Nile, W., Nile, W., Polynesia, F., Fig, E.D., Zikv, T., Fig, E.D., 2016. Structure of the thermally stable ZIKA virus. *Nature* 533, 425–428. <https://doi.org/10.1038/nature17994>.
- Kroschewski, H., Allison, S.L., Heinz, F.X., Mandl, C.W., 2003. Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. *Virology* 308, 92–100. [https://doi.org/10.1016/S0042-6822\(02\)00097-1](https://doi.org/10.1016/S0042-6822(02)00097-1).
- Kuhn, R.J., Dowd, K.A., Beth Post, C., Pierson, T.C., 2015. Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. *Virology* 479–480, 508–517. <https://doi.org/10.1016/j.viro.2015.03.025>.
- Lee, E., Hall, R.A., Lobigs, M., Al, L.E.E.T., Irol, J.V., 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese Encephalitis and West Nile Viruses. *J. Virol.* 78, 8271–8280. <https://doi.org/10.1128/JVI.78.15.8271>.
- Lenke, G., Rothlin, C.V., 2010. Immunobiology of the TAM receptors. *Nat. Rev. Immunol.* 8, 327–336. <https://doi.org/10.1038/nri2303>.
- Lewis, J.K., Bothner, B., Smith, T.J., Siuzdak, G., 1998. Antiviral agent blocks breathing of the common cold virus. *Proc. Natl. Acad. Sci. U. S. A.* 95, 6774–6778.
- Li, C., Deng, Y.-Q., Wang, S., Ma, F., Aliyari, R., Xing-Yao, H., Zhang, N.-N., Watanabe, M., Dong, H.-L., Liu, P., Li, X., Ye, Q., Tian, M., Hong, S., Fan, J., Zhao, H., Li, L., Vishlaghi, N., Buth, J.E., Au, C., Liu, Y., Lu, N., Du, P., Qin, F.X.-F., Zhang, B., Gong, D., Dai, X., Sun, R., Novitch, B.G., Xu, Z., Qin, C.-F., Cheng, G., 2017a. 25-hydroxycholesterol protects host against ZIKA virus infection and its associated microcephaly in a mouse model. *Immunity* 46, 446–456. <https://doi.org/10.1016/j.immuni.2017.02.012>.
- Li, C., Zhu, X., Ji, X., Quanquin, N., Deng, Y., Tian, M., Aliyari, R., Zuo, X., Yuan, L., Khan, S., Li, X., Jung, J.U., Nielsen-saines, K., Qin, F.X., Qin, C., Xu, Z., Cheng, G., 2017b. Chloroquine, a FDA-approved drug, prevents ZIKA virus infection and its associated congenital microcephaly in mice. *EBioMedicine* 24, 189–194. <https://doi.org/10.1016/j.ebiom.2017.09.034>.
- Liang, Q., Luo, Z., Zeng, J., Chen, W., Foo, S., Lee, S., Ge, J., Wang, S., Goldman, S.A., Zlokovic, B.V., Zhao, Z., Jung, J.U., 2016. ZIKA virus NS4A and NS4B proteins deregulate Akt-mTOR signaling in human fetal neural stem cells to inhibit neurogenesis and induce autophagy. *Cell Stem Cell* 19, 663–671. <https://doi.org/10.1016/j.stem.2016.07.019>.
- Liu, S., Delalio, L.J., Isakson, B.E., Wang, T.T., 2016. Brief ultrarapid communication AXL-mediated productive infection of human endothelial cells by ZIKA virus. *Circ. Res.* 119, 1183–1189. <https://doi.org/10.1161/CIRCRESAHA.116.309866>.
- Lozach, P.Y., Burleigh, L., Staropoli, I., Navarro-Sanchez, E., Harriague, J., Virelizier, J.L., Rey, F.A., Desprès, P., Arenzana-Seisdedos, F., Amara, A., 2005. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. *J. Biol. Chem.* 280, 23698–23708. <https://doi.org/10.1074/jbc.M504337200>.

- Martina, B.E.E., Koraka, P., Van Den Doel, P., Rimmelzwaan, G.F., Haagmans, B.L., Osterhaus, A.D.M.E., 2008. DC-SIGN induces infection of cells with glycosylated west nile virus in vitro and virus replication in human dendritic cells induces production of IFN- α and TNF- α . *Virus Res.* 135, 64–71. <https://doi.org/10.1016/j.virusres.2008.02.008>.
- Martinez-pomares, L., 2012. The mannose receptor. *J. Leukoc. Biol.* 92, 1177–1186. <https://doi.org/10.1189/jlb.0512231>.
- Meertens, L., Carnec, X., Lecoin, M.P., Guivel-benhassine, F., Lew, E., Lemke, G., Schwartz, O., Amara, A., 2012. The TIM and TAM families of phosphatidyserine receptors mediate dengue virus entry. *Cell Host Microbe* 12, 544–557. <https://doi.org/10.1016/j.chom.2012.08.009>.
- Meertens, L., Labeau, A., Dejarnac, O., Gressens, P., Schwartz, O., Amara, A., Meertens, L., Labeau, A., Dejarnac, O., Cipriani, S., Sinigaglia, L., Schwartz, O., Amara, A., 2017. Axl Mediates ZIKA virus entry in Human glial cells and modulates innate immune responses report Axl Mediates ZIKA virus entry in human glial cells and modulates innate immune responses. *Cell Rep.* 18, 324–333. <https://doi.org/10.1016/j.celrep.2016.12.045>.
- Mercer, J., Helenius, A., 2010. Apoptotic mimicry: phosphatidyserine-mediated macropinocytosis of vaccinia virus. *Annu. N. Y. Acad. Sci.* 1209, 49–55. <https://doi.org/10.1111/j.1749-6632.2010.05772.x>.
- Mercer, J., Schelhaas, M., Helenius, A., 2010. Virus entry by endocytosis. *Annu. Rev. Biochem.* 79, 803–833. <https://doi.org/10.1146/annurev-biochem-060208-104626>.
- Miller, J.L., deWet, B.J.M., Martinez-Pomares, L., Radcliffe, C.M., Dwek, R.A., Rudd, P.M., Gordon, S., 2008. The mannose receptor mediates dengue virus infection of macrophages. *PLoS Pathog.* 4, e17. <https://doi.org/10.1371/journal.ppat.0040017>.
- Miner, J.J., Diamond, M.S., 2017. Review ZIKA virus pathogenesis and tissue tropism. *Cell Host Microbe* 21, 134–142. <https://doi.org/10.1016/j.chom.2017.01.004>.
- Mounce, B.C., Cesaro, T., Carrau, L., Vallet, T., Vignuzzi, M., 2017. Curcumin inhibits ZIKA and chikungunya virus infection by inhibiting cell binding. *Antivir. Res.* 142, 148–157. <https://doi.org/10.1016/j.antiviral.2017.03.014>.
- Mousavi, S.A., Malerød, L., Berg, T., Kjekken, R., 2004. Clathrin-dependent endocytosis. *Biochem. J.* 16, 1–16. <https://doi.org/10.1042/bj20031000>.
- Munjal, A., Khandia, R., Dhama, K., Sachan, S., Karthik, K., Ruchi, T., Malik, Y.S., Kumar, D., Singh, R.K., Iqbal, H.M.N., Joshi, S.K., 2017. Advances in developing therapies to combat ZIKA virus: current knowledge and future perspectives. *Front. Microbiol.* 8, 1469. <https://doi.org/10.3389/fmicb.2017.01469>.
- Musso, D., Roche, C., Nhan, T.X., Robin, E., Teissier, A., Cao-Lormeau, V.M., 2015. Detection of ZIKA virus in saliva. *J. Clin. Virol.* 68, 53–55. <https://doi.org/10.1016/j.jcv.2015.04.021>.
- Navarro-Sanchez, E., Altmeyer, R., Amara, A., Schwartz, O., Fieschi, F., Virelizier, J.L., Arenzana-Seisdedos, F., Desprès, P., 2003. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. *EMBO Rep.* 4, 723–728. <https://doi.org/10.1038/sj.embor.embor866>.
- Pagani, I., Ghezzi, S., Ulisse, A., Rubio, A., Turrini, F., Garavaglia, E., Candiani, M., Castilletti, C., Ippolito, G., Poli, G., Broccoli, V., Panina-bordignon, P., Vicenzi, E., 2017. Human dendritic stromal cells are highly permissive to productive infection by ZIKA virus. *Nat. Publ. Group* 7. <https://doi.org/10.1038/srep44286>.
- Perera-lecoim, M., Meertens, L., Carnec, X., Amara, A., 2014. Flavivirus entry receptors: an update. *Viruses* 6, 69–88. <https://doi.org/10.3390/v6010069>.
- Persaud, M., Martinez-lopez, A., Bu, C., Porcelli, S.A., Diaz-gri, F., 2018. Infection by ZIKA virus requires the transmembrane protein AXL, endocytosis and low pH. 518, 301–312. <https://doi.org/10.1016/j.virol.2018.03.009>.
- Pierson, T.C., Diamond, M.S., 2013. Degrees of maturity: the complex structure and biology of flaviviruses. *Curr. Opin. Virol.* 2, 168–175. <https://doi.org/10.1016/j.coviro.2012.02.011>.
- Quicke, K.M., Bowen, J.R., Johnson, E.L., Schinazi, R.F., Chakraborty, R., Suthar, M.S., Quicke, K.M., Bowen, J.R., Johnson, E.L., McDonald, C.E., Ma, H., Neal, J.T.O., 2016. ZIKA virus infects human placental macrophages. *Cell Host Microbe* 20, 83–90. <https://doi.org/10.1016/j.chom.2016.05.015>.
- Rausch, K., Hackett, B.A., Weinbren, N.L., Schultz, D.C., Coyne, C.B., Cherry, S., Rausch, K., Hackett, B.A., Weinbren, N.L., Reeder, S.M., Sadovsky, Y., 2017. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against ZIKA virus. *Cell Rep.* 18, 804–815. <https://doi.org/10.1016/j.celrep.2016.12.068>.
- Retalack, H., Di, E., Arias, C., Knopp, K.A., Laurie, M.T., 2016. ZIKA virus cell tropism in the developing human brain and inhibition by azithromycin. *Proc. Natl. Acad. Sci.* 113, 14408–14413. <https://doi.org/10.1073/pnas.1618029113>.
- Rey, A., Stiasny, K., Heinz, F.X., 2017. Flavivirus structural heterogeneity: implications for cell entry. *Curr. Opin. Virol.* 24, 132–139. <https://doi.org/10.1016/j.coviro.2017.06.009>.
- Sandun, F., Teshan, F., Stefanik, M., Eyer, L., Ruzek, D., 2016. An approach for ZIKA virus inhibition using homology structure of the envelope protein. *Mol. Biotechnol.* 58, 801–806. <https://doi.org/10.1007/s12033-016-9979-1>.
- Schuler-faccini, L., Ribeiro, E.M., Feitosa, I.M.L., Horovitz, D.D.G., Cavalcanti, D.P., 2016. Possível associação entre a infecção pelo vírus ZIKA E a microcefalia — Brasil, 2015. *In: Cent. Dis. Control Prev. - Morb. Mortal. Wkly Rep.* 65, pp. 1–4.
- Shi, Y., Gao, G.F., 2017. Structural biology of the ZIKA virus. *Trends Biochem. Sci.* 42, 443–456. <https://doi.org/10.1016/j.tibs.2017.02.009>.
- Shimajima, M., Takenouchi, A., Shimoda, H., Kimura, N., Maeda, K., 2014. Distinct usage of three C-type lectins by Japanese encephalitis virus: DC-SIGN, DC-SIGNR, and LSECtin. *Arch. Virol.* 159, 2023–2031. <https://doi.org/10.1007/s00705-014-2042-2>.
- Shiryaev, S.A., Mesci, P., Pinto, A., Fernandes, I., Sheets, N., Shrestha, S., Farhy, C., Huang, C.-T., Strongin, A.Y., Muotri, A.R., Terskikh, A.V., 2017. Repurposing of the anti-malaria drug chloroquine for ZIKA virus treatment and prophylaxis. *Sci. Rep.* 7, 15771. <https://doi.org/10.1038/s41598-017-15467-6>.
- Simpson, D.I.H., 1964. ZIKA virus infection in man. *Trans. R. Soc. Trop. Med. Hyg.* 58, 335–338. [https://doi.org/10.1016/0035-9203\(64\)90200-7](https://doi.org/10.1016/0035-9203(64)90200-7).
- Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., Kuhn, R.J., 2016. The 3.8 Å resolution cryo-EM structure of ZIKA virus. *Science* 352 (80), 467–470. <https://doi.org/10.1126/science.aaf5316>.
- Smit, J.M., Moesker, B., Rodenhuis-zybert, I., Wilschut, J., 2011. Flavivirus cell entry and membrane fusion. *Virus* 3, 160–171. <https://doi.org/10.3390/v3020160>.
- Su, C.M., Liao, C.L., Lee, Y.L., Lin, Y.L., 2001. Highly sulfated forms of heparin sulfate are involved in Japanese encephalitis virus infection. *Virology* 286, 206–215. <https://doi.org/10.1006/viro.2001.0986>.
- Tabata, T., Pettitt, M., Puerta-guardo, H., Fang-hoover, J., Harris, E., Tabata, T., Pettitt, M., Puerta-guardo, H., Michlmayr, D., Wang, C., Fang-hoover, J., 2016. ZIKA virus targets different primary human placental cells, suggesting two routes for vertical transmission. *Cell Host Microbe* 20, 1–12. <https://doi.org/10.1016/j.chom.2016.07.002>.
- Tan, C.W., Sam, I.-C., Chong, W.L., Lee, V.S., Chan, Y.F., 2017. Polysulfonate suramin inhibits ZIKA virus infection. *Antivir. Res.* 143, 186–194. <https://doi.org/10.1016/j.antiviral.2017.04.017>.
- Tang, H., Hammack, C., Ogden, S.C., Wen, Z., Qian, X., Li, Y., Yao, B., Shin, J., Zhang, F., Lee, E.M., Christian, K.M., Didier, R.A., Jin, P., Song, H., Ming, G., 2016. ZIKA virus infects human cortical neural progenitors and attenuates their growth brief report zika virus infects human cortical neural progenitors and attenuates their growth. *Stem Cells* 18, 587–590. <https://doi.org/10.1016/j.stem.2016.02.016>.
- Tassanetri, B., Burgess, T.H., Granelli-Piperno, A., Trumppfeller, C., Finke, J., Sun, W., Eller, M.A., Pattanapanyasat, K., Sarasombath, S., Birx, D.L., Steinman, R.M., Schlesinger, S., Marovich, M.A., 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. *J. Exp. Med.* 197, 823–829. <https://doi.org/10.1084/jem.20021840>.
- Thepparit, C., Phoolcharoen, W., Suksanpaisan, L., Smith, D.R., 2004. Internalization and propagation of the dengue virus in human hepatoma (HepG2) cells. *Intervirology* 73/70, 78–86. <https://doi.org/10.1159/00007830>.
- Wang, L., Chen, R.F., Liu, J.W., Lee, I.K., Lee, C.P., Kuo, H.C., Huang, S.K., Yang, K.D., 2011. DC-SIGN (CD209) promoter – 336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. *PLoS Negl. Trop. Dis.* 5. <https://doi.org/10.1371/journal.pntd.0000934>.
- Wang, P., Hu, K., Luo, S., Zhang, M., Deng, X., Li, C., Jin, W., Hu, B., He, S., Li, M., Du, T., Xiao, G., Zhang, B., Liu, Y., Hu, Q., 2016. DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein. *Virology* 488, 108–119. <https://doi.org/10.1016/j.virol.2015.11.006>.
- Wang, A., Thurmond, S., Islas, L., Hui, K., Hai, R., 2017a. ZIKA virus genome biology and molecular pathogenesis. *Nat. Publ. Group* 13, 1–6. <https://doi.org/10.1038/emi.2016.141>.
- Wang, Z., Wang, Z., Zhen, Z., Feng, K., Guo, J., Gao, N., Fan, D., Han, D., Barr, G., 2017b. Axl is not an indispensable factor for Zika virus infection in mice. *J. Gen. Virol.* 98, 2061–2068. <https://doi.org/10.1099/jgv.0.000886>.
- Wells, M.F., Salick, M.R., Wiskow, O., Ye, C., Kaykas, A., Eggan, K., Wells, M.F., Salick, M.R., Wiskow, O., Ho, D.J., Worringer, K.A., Ihry, R.J., 2016. Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection brief report genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from ZIKA virus infection. *Stem Cells* 19, 703–708. <https://doi.org/10.1016/j.stem.2016.11.011>.
- Ye, Q., Liu, Z.Y., Han, J.F., Jiang, T., Li, X.F., Qin, C.F., 2016. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. *Infect. Genet. Evol.* 43, 43–49. <https://doi.org/10.1016/j.meegid.2016.05.004>.
- Yu, I.-M., Zhang, W., Holdaway, H.A., Li, L., Kostyuchenko, V.A., Chipman, P.R., Kuhn, R.J., Rossmann, M.G., Chen, J., 2014. Structure of the immature dengue virus at low pH primes proteolytic maturation. *Science* (80-) 319, 1834–1837. <https://doi.org/10.1126/science.1153264>.
- Yuan, L., Huang, X.-Y., Liu, Z.-Y., Zhang, F., Zhu, X.-L., Yu, J.-Y., Ji, X., Xu, Y.-P., Li, G., Li, C., Wang, H.-J., Deng, Y.-Q., Wu, M., Cheng, M.-L., Ye, Q., Xie, D.-Y., Li, X.-F., Wang, X., Shi, W., Hu, B., Shi, P.-Y., Xu, Z., Qin, C.-F., 2017. A single mutation in the prM protein of ZIKA virus contributes to fetal microcephaly. *Science* 88 (80), 11726–11737. <https://doi.org/10.1126/JVI.01140-14>.
- Zelensky, A.N., Gready, J.E., 2005. The C-type lectin-like domain superfamily. *FEBS J.* 272, 6179–6217. <https://doi.org/10.1111/j.1742-4658.2005.05031.x>.
- Zhang, Y., Chipman, P.R., Kuhn, R.J., Rossmann, M.G., 2007. Structure of immature west nile virus. *J. Virol.* 81, 6141–6145. <https://doi.org/10.1128/JVI.00037-07>.
- Zhang, Z., Li, Z., Yuan, S., 2017. The role of secretory autophagy in zika virus transfer through the placental barrier. *Front. Cell. Infect. Microbiol.* 6, 206. <https://doi.org/10.3389/fcimb.2016.00206>.